Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

In the news

EU to review Shire's Intuniv extended-release PharmaTimes, Mar 27, 2014
Will Shire PLC Build Or Buy Its Future? The Motley Fool, Mar 26, 2014
Shire PLC PT Raised to $173.00 at JPMorgan Chase & Co. (SHPG) American Banking News, Mar 25, 2014
Shire Recalls Gaucher Drug Vpriv, Mar 18, 2014
UBS AG Reiterates 'Neutral' Rating for Shire PLC American Banking News, Mar 14, 2014
ADHD big money for big pharma CNBC, Mar 12, 2014
Shire (SHPG): Strong Industry, Solid Earnings Estimate Revisions, Mar 7, 2014
Market report: Shire stalls amid analyst caution, Mar 6, 2014
Shire Faces Patent Suit Revival Over Lialda Colitis Drug Bloomberg, Feb 28, 2014
Shire Chairman sells shares following 'excellent' 2013 results, Feb 21, 2014
Shire aims for US binge-eating breakthrough, Feb 14, 2014
Questor share tip: Shire sales accelerate, Feb 14, 2014
Shire’s Vyvanse could bring in new revenue, Feb 14, 2014
Shire Beats in Q4, Positive Guidance, Feb 14, 2014
Shire facility in Lexington gets FDA approval to manufacture Gaucher disease drug, Feb 14, 2014
New Lifetime High Today: Shire (SHPG), Feb 13, 2014
Rosy Outlook for Shire, Finance Chief to Leave, Feb 13, 2014
Shire steers Vyvanse toward binge eating as earnings come up aces FiercePharma, Feb 13, 2014
Shire profits boosted by rare disease success, Feb 13, 2014
Shire Says Chief Financial Officer to Step Down, Feb 13, 2014
Shire abandons move into depression after disappointing trial results, Feb 7, 2014
Shire Ends Research Into Vyvanese’s Use in Depression, Feb 7, 2014
Shire’s Vyvanse Fails to Ease Depression in Studies Bloomberg, Feb 7, 2014
Depressing news for Shire drug's use The Times, Feb 7, 2014
Shire's ADHD drug Vyvanse fails in trial to treat depression Reuters, Feb 6, 2014
Equality in the Workplace, Feb 5, 2014
Hopes of family, firm collide on unproven drug, Jan 31, 2014
Shire's Susan Kilsby to Succeed Matthew Emmens as Chairman, Jan 23, 2014
Former Credit Suisse banker to take the helm at Shire, Jan 23, 2014
Susan Kilsby appointed to helm of Shire and doubles FTSE chairwomen, Jan 23, 2014
Shire taps ex-investment banker Susan Kilsby to chair its board, Jan 23, 2014
Shire has a partially built plant for sale after unloading Dermagraft, Jan 20, 2014
Shire to Take Loss on Dermagraft Sale, Jan 17, 2014
Shire takes an L on Dermagraft, unloads it to Organogenesis, Jan 17, 2014
Shire divests failing Dermagraft to Organogenesis, Jan 17, 2014
Shire shares rise despite $650m hit after selling Dermagraft business, Jan 17, 2014
Shire takes $650 mln hit on Dermagraft sale, Jan 17, 2014
Shire share price hits record high on profit outlook upgrade, Jan 15, 2014
Shire is not quite to the finish line with ViroPharma, Jan 10, 2014

Our global reach

Our products are marketed in over 50 countries worldwide, and we now have offices in 29 countries. View our interactive map, and learn more
about our global reach.

Our locations